Flags

Earnings warning

Protagonist Therapeutics

NMQ:PTGX · US74366E1029

BiotechnologySmall

360

Value39

Profit price75

EV / EBIT50

Price / Owner Earnings100

Cash yield1

Sales & asset price34

Price/Sales64

EV / Gross Profit13

Price/Book25

Quality50

Returns on capital60

Return on Capital56

Cash Return on Capital60

Return on Equity65

Profit margins22

EBIT Margin5

Gross Profitability39

Cash backing58

Accruals87

Owner Earnings Margin29

Growth53

Sales growth100

Profit growth38

Profit Growth98

Long-Term EPS Growth14

Owner Earnings Growth1

Reinvestment78

Price momentum72

Safety33

Debt load66

Debt serviceability51

Refinancing100

Debt Payback1

Liquidity10

Sentiment50

Analyst ratings33

Expectations trend53

Opinion Changes84

Price Target Upside21

Market mood63

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Protagonist Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2006

Employees125

Websiteprotagonist-inc.com

ISINUS74366E1029

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

ImmunologyHematologyInflammationObesityDermatologyEndocrinologyBiotechnologyHealth CareMedical

Description

Protagonist Therapeutics, Inc. is a discovery through late-stage development biopharmaceutical company focused on peptide therapeutics. The company’s programs fall into three broad therapeutic areas: (i) inflammation and immunology (‘I&I’), (ii) hem…

Analysis

Middle-of-the-road

Protagonist Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Protagonist Therapeutics with its peers

Oruka Therapeutics

NMQ:ORKA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Apogee Therapeutics

NMQ:APGE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Monte Rosa Therapeutics

NSQ:GLUE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Monopar Therapeutics

NAQ:MNPR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Disc Medicine

NMQ:IRON

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →